Agios Pharmaceuticals Inc. (NASDAQ: AGIO) disclosed that its chief financial officer, Cecilia Jones, sold 3,141 shares of the companys common stock on April 2, 2026, at a price of $34.71 per share. The transaction totaled $109,024 and, according to a Form 4 filed with the Securities and Exchange Commission, was undertaken to satisfy the tax withholding obligation associated with the vesting of performance share units.
The filing specifies that the disposition was executed pursuant to a pre-arranged Rule 10b5-1 trading plan that Jones established on March 1, 2024. On the same date as the sale, Jones exercised options to acquire 8,500 shares of Agios common stock at a price of $0, reflecting the vesting of performance share units that had been granted on March 1, 2024. Those performance share units vested as to 50% of the underlying shares upon the achievement of a regulatory milestone on April 2, 2026.
Post-transaction, Joness direct holdings in Agios total 54,998 shares, a sum that includes 311 shares acquired through the companys employee stock purchase plan. The SEC filing frames the sale strictly as a tax-related disposal of vested shares rather than as a discretionary cash-raising or signal of strategic change.
Market context noted in data from InvestingPro indicates Agios stock has climbed nearly 19% over the previous week. Those same data show the company trading below its Fair Value estimate of $42.56, which places AGIO among names flagged as undervalued within the biotech sector by that measure. Investors interested in deeper company analysis are pointed to comprehensive Pro Research Reports and more than 10 additional InvestingPro Tips available to subscribers.
Separately, Agios reported regulatory progress tied to its mitapivat program in sickle cell disease. The company said a pre-supplemental New Drug Application meeting with the U.S. Food and Drug Administration resulted in a recommendation that Agios submit a proposal for a confirmatory clinical trial as part of pursuing potential U.S. accelerated approval. The regulatory interaction and the related milestone triggered the vesting of a portion of the performance share units awarded to Jones.
Brokerage coverage and analyst commentary following these developments include Truist Securities reiterating a Buy rating with a $39.00 price target, and BofA Securities raising its target to $44.00, citing increased confidence in the approval pathway for the drug. The broader competitive context referenced in filings and analyst notes mentions Fulcrum Therapeutics, with Stifel observing that Fulcrum shares remain undervalued given FDA flexibility in the sickle cell treatment space; Leerink Partners reiterated an Outperform rating for Fulcrum with a $47.00 target.
The combination of insider activity, analyst reassessments, and regulatory progress outlines the immediate developments affecting Agios shares. The CFOs sale was limited in scope and was explicitly tied to tax withholding from vested performance awards, while related clinical and regulatory milestones continue to shape analyst views and price targets in the sector.
Summary of Transactions
- Sale: 3,141 shares sold on April 2, 2026, at $34.71 per share, totaling $109,024.
- Exercise/Vesting: Options exercised for 8,500 shares at $0; 50% of PSUs vested upon regulatory milestone on April 2, 2026.
- Post-transaction holdings: 54,998 shares directly owned, including 311 via the employee stock purchase plan.